cnbc semaglutide New GLP-1 news: reports a tiny implant is the latest bet to help patients maintain weight loss. Important context: this is early-stage research and business news, not a currently approved CNBC investigates the black market

GLP-1 drugs like Ozempic and Wegovy change food cravings and taste preferencesleading to weight loss beyond just reduced appetite.

Learn how dehydration, weight loss, and side effects may affect kidney health, plus prevention tips.

We are developing a number of novel programs for the treatment of neurological and metabolic disorders.

People with chronic kidney disease, of which type2 diabetes is the most common cause, are at high risk for kidney failure, cardiovascular events and death.

Carefully selected blend of premium ingredients works synergistically t

The appeal applies to GLP-1 drugs approved for weight lossliraglutide, semaglutide, and tirzepatideas GLP-1 medications approved solely for type 2 diabetes do not currently include a suicidal ideation and behavior warning.